Navigation Links
La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial

t maintaining antibody reductions over time in individual patients was associated with a significantly reduced renal flare rate. The updated data indicate that the higher the Riquent dose, the greater the consistency of response and the greater the magnitude of this response. While more than twice as many 900 mg-treated patients (62%) as 100 mg-treated patients (25%) had a consistent 20% reduction, nearly seven times as many 900 mg-treated patients (42%) had a consistent 40% reduction, compared with 100 mg-treated patients (6%). Nearly twice as many patients on 900 mg as 300 mg had a consistent 50% reduction, but no patients on 100 mg or placebo achieved this level of consistent reduction. A consistent reduction is defined as a patient whose percent antibody reduction exceeded a specified level at weeks 4, 6 and 8.

Tolerability

To date, Riquent has been well tolerated in the ongoing Phase 3 study. The adverse event profile for all patients in the study, including those treated with the 300 mg and 900 mg doses, does not appear to differ from that seen in previous studies where 100 mg of Riquent was the treatment dose.

These data will be presented at the 8th International Congress on SLE in Shanghai in May 2007.

Phase 3 Study Design

The Phase 3 study is designed to assess the ability of Riquent treatment to prevent or delay the time to renal flare in lupus patients with a history of renal disease and with antibodies to dsDNA. A lupus renal flare is a potentially life-threatening increase in inflammation targeting the kidney. A renal flare often requires treatment with immunosuppressive agents which can have severe side effects.

The global study is expected to enroll approximately 730 patients who will be treated weekly with Riquent or placebo. Equal numbers of patients will be treated with 300 mg per week, 900 mg per week or placebo for 12 months. Patient enrollment in this international study recommenced in the third quarter
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/25/2014)... Cardinal Health will today name three of the nation,s ... Independent Pharmacy Best Practices Competition, during the company,s ... gatherings of independent pharmacists. The Best ... Ohio , Tennessee and ... implementing exceptionally creative methods that demonstrate how independent pharmacies ...
(Date:7/25/2014)... 2014  Solanbridge Group Inc (OTC: SLNX) is pleased ... in Buzznbrewz.com and the Letter of Intent issued on ... executed Purchase Agreement. Charles R. Shirley ... to have Mr. David Pecoraro and Buzznbrewz.com ... the private sector and developed a tremendous network of ...
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4
... Nektar Therapeutics,(Nasdaq: NKTR ) announced ... its pipeline programs will be presented at ... months. These presentations will,highlight Nektar,s novel therapeutic ... central nervous system (CNS), which leverage Nektar,s,innovative ...
... Leading RSV,investigator Dr. John DeVincenzo has taken another ... bronchiolitis and pneumonia,according to the Centers for Disease Control. ... of hospitalization of infants in the US and,one of ... group., DeVincenzo is using the process of RNAi ...
Cached Medicine Technology:Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings 2Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings 3Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings 4RSV Researcher Makes Gains in Finding Treatments 2
(Date:7/27/2014)... Bags underneath the eyes is one condition that ... are a range of new products now available from Internet ... eyes serum review that is now posted for adults to ... issues with baggy eyes and how the natural ingredients in ... guide also provides a detailed overview of the creams and ...
(Date:7/27/2014)... 27, 2014 Ticket Down is a ... Forum in Inglewood, California on November 15th. This Australian ... can expect to hear songs from this amazing album at the ... in Inglewood, California at The Forum will be released for sale ... a.m. today local time TicketDown.com. This popular secondary ticket exchange ...
(Date:7/27/2014)... University of Manchester have discovered why medication to treat asthma ... Nature Medicine , show that drugs widely used to ... , In the UK pneumonia, which is caused by an ... is more serious for babies, young children, the elderly, smokers ... than 5 million people in the UK are affected by ...
(Date:7/27/2014)... July 27, 2014 The North American ... estimated at $1570 million in 2014, and it is ... CAGR of 4.64%. The report incorporates the factors that ... expectations of growth rates and projected total expenditure. The ... the global markets. Apart from the general overview of ...
(Date:7/27/2014)... The European Agricultural Adjuvants Market report defines and segments ... of revenue. The agricultural adjuvants market in Europe is ... to $657.1 million by 2018, at a CAGR of ... TOC of the European Agricultural Adjuvants Market report, to ... also provides a glimpse of the segmentation in the ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Drugs used to treat lung disease work with the body clock 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5
... The patent expiry of blockbuster molecules ... intense competition from generics. CEOs have had ... to maintain the growth of their organisation ... on the market for niche blockbuster drugs ...
... Peanut Field, Product Sampling March 4 and 5NEW YORK, Feb. ... up shop in Vanderbilt Hall in New York City,s Grand ... questions and give away samples of peanuts, peanut butter and ... efforts nationally to rebuild consumer confidence in products made with ...
... Feb. 25 HealthFitness Corporation (NYSE Alternext ... and productivity management solutions, will conduct a conference call ... and year ended December 31, 2008. The call is ... 2009.Participants can dial (888) 396-5640 or (706) 643-0580 to ...
... N.J., Feb. 25 Psychiatric ... one of the nation,s leading experts in the field ... director of psychiatric drug research at the R/D Clinical ... special interest in the therapeutic areas of depression and ...
... Center for Wellbeing today announced its Chopra en ... Spanish speakers seeking out the Center,s programs and ... and human empowerment.(Photo: http://www.newscom.com/cgi-bin/prnh/20080617/LATU012 )"In the ... I first had the idea to create a ...
... on the future of SBIR grants in Washington, DC as a means ... being explicitly excluded from NIH stimulus money. Federal reauthorization or a continuing ... ... 25, 2009 -- Looking for funding for small business ventures ...
Cached Medicine News:Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 2Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 3Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 4Health News:America's Peanut Farmers to Travel to New York City to Meet Consumers, Work to Rebuild Trust in All Things Peanut 2Health News:Psychiatric Congress 2009 Announces Rakesh Jain, MD, MPH, as Program Chair 2Health News:The Chopra Center Introduces Mind-body Health Programs for Spanish Speakers: Chopra en Espanol Connects Spanish Speakers Worldwide to Deepak Chopra and David Simon's Global Message of Wellness 2Health News:The Commercialization Funding Coach, Fred Patterson, Weighs In On SBIR Funding for Small Business Ventures in Wake of NIH Exclusion 2Health News:The Commercialization Funding Coach, Fred Patterson, Weighs In On SBIR Funding for Small Business Ventures in Wake of NIH Exclusion 3
... Field (PEMF) bone growth stimulation delivered by ... long bone and small bone nonunions. Physio-Stim ... brace, or clothing without lessening its effectiveness. ... compact, lightweight unit including success rates as ...
Our products, with carefully researched design features, are tailored to making arthroscopic and ligament reconstructive surgery more reproducible, easier, quicker and safer....
... Screws. Optimal screw design ... selection options. Robust threads ... and chamfered screw hub ... tissue fixation. Features a ...
Cannulated Interference Screws...
Medicine Products: